UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 37,870 Shares of Certara, Inc. (NASDAQ:CERT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 16.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 263,574 shares of the company's stock after purchasing an additional 37,870 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.16% of Certara worth $2,807,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Venturi Wealth Management LLC grew its position in Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after acquiring an additional 2,509 shares during the period. Wells Fargo & Company MN grew its position in Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after acquiring an additional 1,047 shares during the period. Johnson Financial Group Inc. purchased a new position in Certara in the fourth quarter worth approximately $47,000. Blue Trust Inc. grew its position in Certara by 20.9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after acquiring an additional 822 shares during the period. Finally, ANTIPODES PARTNERS Ltd grew its position in Certara by 204.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock worth $58,000 after acquiring an additional 3,656 shares during the period. Institutional investors and hedge funds own 73.96% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th. Stephens restated an "overweight" rating and set a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. Robert W. Baird raised their price target on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. William Blair restated a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Finally, KeyCorp raised their price target on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $15.67.

Certara Stock Up 0.5%

NASDAQ CERT traded up $0.06 during trading hours on Friday, hitting $11.76. The company had a trading volume of 1,355,029 shares, compared to its average volume of 1,358,596. Certara, Inc. has a fifty-two week low of $8.64 and a fifty-two week high of $17.22. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -58.80, a P/E/G ratio of 9.29 and a beta of 1.44. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The firm's 50 day moving average is $12.02 and its 200 day moving average is $11.83.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. The company had revenue of $106.00 million during the quarter, compared to analysts' expectations of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.10 EPS. Sell-side analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.